In breast cancer, it was demonstrated that H19 inhibits SAHH, resulting in the accumulation of SAH, which restricts DNMT3B from methylating Beclin1 promoter and inducing the upregulation of Beclin1 and subsequently initiates autophagy, contributing to tamoxifen resistance [86]. Here, H19 is linked to breast carcinoma.